This was a Phase 1, single-center, randomized, placebo-controlled, 2-period, ascending
single-dose study assessing the PK, safety, and tolerability of single ascending doses of
XG005 (Period 1) and the naproxen and pregabalin combination (Period 2), in 5 dose groups
each with 10 subjects.